Publications

 

You can browse our selected publications below. Follow the link to visit PubMed website.

Dennler P. et al.

Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates

Bioconjug Chem. 2014 March 19

2014/02 - volume: 25 - pages: 569-78.

Kohrt H. E. et al.

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Blood. 2014 Jan 30

2013/12 - volume: 123 - pages: 678-86.

Vey N. at al.

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Blood. 2012 Nov 22

2012/10 - volume: 120 - pages: 4317-23.

Mediouni S. et al.

A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade

J Biol Chem. 2012 Apr 6

2012/03 - volume: 287 - pages: 11942-50.

Thielens A., Vivier E., Romagne F.

NK cell MHC class I specific receptors (KIR): from biology to clinical intervention

Curr Opin Immunol. 2012 Apr;24

2012/03 - volume: 24 - pages: 239-45.

Benson D. M. Jr. et al.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Blood. 2011 Dec 8

2011/11 - volume: 118 - pages: 6387-91.

Salaun B. et al.

TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer

Cancer Res. 2011 Mar 1

2011/02 - volume: 71 - pages: 1607-14.

Romagne F., Vivier E.

Natural killer cell-based therapies

F1000 Med Rep. 2011

2010/12 - volume: 3 - pages: 9.

Gilabert M., Audebert S., Viens P., Borg J. P., Bertucci F., Goncalves A.

[Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers]

Bull Cancer. 2010 Mar

2010/02 - volume: 97 - pages: 321-39.

Vahlne G. et al.

In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2

Eur J Immunol - 2010 Mar

2010/02 - volume: 40 - pages: 813-23.

Johansson S. E. et al.

NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients

Clin Immunol. 2010 Feb

2010/01 - volume: 134 - pages: 158-68.

Romagne F. et al.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

Blood. 2009 Sep 24

2009/08 - volume: 114 - pages: 2667-77.

Sola C. et al.

Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo

Proc Natl Acad Sci U S A. 2009 Aug 4

2009/07 - volume: 106 - pages: 12879-84.

Benkoel L. et al.

Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues

Mol Cancer Ther. 2009 Feb

2009/01 - volume: 8 - pages: 282-91.

Despoix N, et al.

Mouse CD146/MCAM is a marker of natural killer cell maturation

Eur J Immunol. 2008 Oct

2008/09 - volume: 38 - pages: 2855-64.

Anfossi N. et al.

Human NK cell education by inhibitory receptors for MHC class I

Immunity. 2006 Aug

2006/07 - volume: 25 - pages: 331-42.

Charafe-Jauffret E. et al.

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'

J Pathol. 2004 Mar

2004/02 - volume: 202 - pages: 265-73.

Ugolini S. et al.

Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells

Nat Immunol. 2001 May

2001/04 - volume: 2 - pages: 430-5.

Cambiaggi A. et al.

Modulation of T-cell functions in KIR2DL3 (CD158b) transgenic mice

Blood. 1999 Oct 1

1999/09 - volume: 94 - pages: 2396-402.

Pierres M. et al.

Fine specificity of antibodies to poly(Glu60Ala30Tyr10) produced by hybrid cell lines

Proc Natl Acad Sci U S A. 1979 May

1979/04 - volume: 76 - pages: 2425-9.